Johnson & Johnson Valuation
Is JNJ * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JNJ * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JNJ * (MX$2549) is trading below our estimate of fair value (MX$3178.86)
Significantly Below Fair Value: JNJ * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JNJ *?
Other financial metrics that can be useful for relative valuation.
What is JNJ *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$364.32b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.3x |
Enterprise Value/EBITDA | 12.1x |
PEG Ratio | 3.1x |
Price to Earnings Ratio vs Peers
How does JNJ *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 48.8x | ||
LAB B Genomma Lab Internacional. de | 15.1x | 28.6% | Mex$16.1b |
MRK Merck | 141.3x | 24.9% | US$327.5b |
ROG Roche Holding | 15.6x | 8.6% | CHF181.3b |
NOVN Novartis | 23.1x | 10.0% | CHF190.8b |
JNJ * Johnson & Johnson | 21.5x | 6.9% | Mex$364.3b |
Price-To-Earnings vs Peers: JNJ * is good value based on its Price-To-Earnings Ratio (21.5x) compared to the peer average (49.6x).
Price to Earnings Ratio vs Industry
How does JNJ *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Earnings vs Industry: JNJ * is good value based on its Price-To-Earnings Ratio (21.5x) compared to the Global Pharmaceuticals industry average (25.4x).
Price to Earnings Ratio vs Fair Ratio
What is JNJ *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 21.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate JNJ *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$2,549.00 | Mex$2,891.57 +13.4% | 7.7% | Mex$3,588.09 | Mex$2,586.76 | n/a | 21 |
May ’25 | Mex$2,485.00 | Mex$2,948.58 +18.7% | 7.7% | Mex$3,658.83 | Mex$2,637.76 | n/a | 21 |
Apr ’25 | Mex$2,624.62 | Mex$2,922.11 +11.3% | 7.1% | Mex$3,581.69 | Mex$2,665.44 | n/a | 21 |
Mar ’25 | Mex$2,739.91 | Mex$2,970.32 +8.4% | 7.5% | Mex$3,665.21 | Mex$2,676.46 | n/a | 21 |
Feb ’25 | Mex$2,723.00 | Mex$2,993.59 +9.9% | 7.4% | Mex$3,687.42 | Mex$2,692.68 | n/a | 22 |
Jan ’25 | Mex$2,645.81 | Mex$3,001.26 +13.4% | 7.2% | Mex$3,691.10 | Mex$2,695.36 | n/a | 22 |
Dec ’24 | Mex$2,745.48 | Mex$3,001.66 +9.3% | 7.4% | Mex$3,697.36 | Mex$2,665.54 | n/a | 22 |
Nov ’24 | Mex$2,664.84 | Mex$3,211.42 +20.5% | 6.9% | Mex$3,920.01 | Mex$2,862.52 | n/a | 22 |
Oct ’24 | Mex$2,714.00 | Mex$3,079.44 +13.5% | 6.5% | Mex$3,682.11 | Mex$2,705.92 | n/a | 21 |
Sep ’24 | Mex$2,733.99 | Mex$3,093.53 +13.2% | 6.0% | Mex$3,674.63 | Mex$2,802.97 | n/a | 21 |
Aug ’24 | Mex$2,848.00 | Mex$3,053.34 +7.2% | 6.1% | Mex$3,600.05 | Mex$2,746.08 | n/a | 20 |
Jul ’24 | Mex$2,838.00 | Mex$3,169.76 +11.7% | 6.9% | Mex$3,803.01 | Mex$2,847.83 | n/a | 20 |
Jun ’24 | Mex$2,713.52 | Mex$3,169.76 +16.8% | 6.9% | Mex$3,803.01 | Mex$2,847.83 | n/a | 20 |
May ’24 | Mex$2,931.10 | Mex$3,235.64 +10.4% | 7.1% | Mex$3,890.96 | Mex$2,913.70 | Mex$2,485.00 | 19 |
Apr ’24 | Mex$2,800.00 | Mex$3,219.92 +15.0% | 7.2% | Mex$3,891.31 | Mex$2,913.96 | Mex$2,624.62 | 21 |
Mar ’24 | Mex$2,765.00 | Mex$3,244.73 +17.4% | 7.0% | Mex$3,892.12 | Mex$2,914.57 | Mex$2,739.91 | 21 |
Feb ’24 | Mex$3,070.32 | Mex$3,395.35 +10.6% | 6.5% | Mex$4,035.38 | Mex$3,078.15 | Mex$2,723.00 | 20 |
Jan ’24 | Mex$3,448.00 | Mex$3,554.15 +3.1% | 7.1% | Mex$4,199.64 | Mex$3,125.31 | Mex$2,645.81 | 22 |
Dec ’23 | Mex$3,422.00 | Mex$3,491.13 +2.0% | 7.1% | Mex$4,118.48 | Mex$3,064.91 | Mex$2,745.48 | 20 |
Nov ’23 | Mex$3,378.00 | Mex$3,658.46 +8.3% | 7.0% | Mex$4,323.05 | Mex$3,217.15 | Mex$2,664.84 | 21 |
Oct ’23 | Mex$3,338.99 | Mex$3,686.23 +10.4% | 6.6% | Mex$4,282.26 | Mex$3,266.47 | Mex$2,714.00 | 19 |
Sep ’23 | Mex$3,327.83 | Mex$3,706.26 +11.4% | 6.4% | Mex$4,300.65 | Mex$3,300.50 | Mex$2,733.99 | 19 |
Aug ’23 | Mex$3,550.00 | Mex$3,834.99 +8.0% | 6.4% | Mex$4,443.58 | Mex$3,410.19 | Mex$2,848.00 | 19 |
Jul ’23 | Mex$3,598.97 | Mex$3,770.76 +4.8% | 6.3% | Mex$4,328.94 | Mex$3,362.48 | Mex$2,838.00 | 18 |
Jun ’23 | Mex$3,484.00 | Mex$3,669.48 +5.3% | 6.4% | Mex$4,203.06 | Mex$3,264.70 | Mex$2,713.52 | 17 |
May ’23 | Mex$3,746.35 | Mex$3,796.46 +1.3% | 7.1% | Mex$4,339.13 | Mex$3,370.39 | Mex$2,931.10 | 18 |
Analyst Forecast: Target price is less than 20% higher than the current share price.